STOCK TITAN

Viridian Therapeutics to Present at the Ladenburg Thalmann 2021 Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on innovative treatments for serious diseases, announced that its CEO, Jonathan Violin, Ph.D., will present at the Ladenburg Thalmann 2021 Healthcare Conference on July 14, 2021, at 9:00 a.m. ET. The event will be held virtually, and the presentation can be accessed through Viridian's website. The company is known for its monoclonal antibody program, VRDN-001, targeting Thyroid Eye Disease (TED), which causes significant discomfort and potential blindness.

Positive
  • None.
Negative
  • None.

BOULDER, Colo., July 07, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies, today announced that Jonathan Violin, Ph.D., President and Chief Executive Officer of Viridian, will present a company overview at the virtual Ladenburg Thalmann 2021 Healthcare Conference taking place July 13 – 14, 2021.

Event:Ladenburg Thalmann 2021 Healthcare Conference
Date:Wednesday, July 14
Presentation Time:9:00 a.m. ET

The webcast information for this event will be accessible on the Events page under the Investors section of the Viridian Therapeutics website at www.viridiantherapeutics.com. A replay of the presentation will be archived on the website and available for approximately 90 days following the live event.

About Viridian Therapeutics

Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is an anti-IGF-1R monoclonal antibody in development for TED, a debilitating auto-immune disease that causes inflammation and fibrosis within the orbit of the eye which can cause double vision, pain, and potential blindness. Patients with severe disease often require multiple remedial surgeries to the orbit, eye muscles, and eyelids. Viridian is based in Boulder, Colorado, and Waltham, Massachusetts. Learn more about Viridian and its programs at https://www.viridiantherapeutics.com/.

Follow us on Twitter @ViridianThera and on LinkedIn.

Viridian Contacts:
Investors:
Dan Ferry
LifeSci Advisors
617-430-7576
IR@viridiantherapeutics.com

Media:
Darby Pearson
Verge Scientific Communications
703-587-0831
PR@viridiantherapeutics.com


FAQ

When is Viridian Therapeutics presenting at the Ladenburg Thalmann 2021 Healthcare Conference?

Viridian Therapeutics will present on July 14, 2021, at 9:00 a.m. ET.

Where can I watch the Viridian Therapeutics presentation?

The presentation can be accessed on Viridian's website under the Events section.

What is VRDN-001 developed by Viridian Therapeutics?

VRDN-001 is an anti-IGF-1R monoclonal antibody in development for Thyroid Eye Disease (TED).

What is the focus of Viridian Therapeutics?

Viridian Therapeutics focuses on developing treatments for serious diseases that are underserved by current therapies.

Viridian Therapeutics, Inc.

NASDAQ:VRDN

VRDN Rankings

VRDN Latest News

VRDN Stock Data

1.59B
76.37M
0.01%
112%
13.12%
Biotechnology
Services-medical Laboratories
Link
United States of America
WALTHAM